| 1 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators) N Engl J Med 2022 Mar 24;386(12):1132-1142 153 Citations |
| 1 | Glucocorticoid Receptor Antagonist Alters Corticosterone and Receptor-sensitive mRNAs in the Hypoxic Neonatal Rat. (Gehrand AL, Phillips J, Welhouse KD, Siddiqui H, Schulgit M, Hoffman J, Hunt H, Raff H) Endocrinology 2022 Jan 01;163(1) 1 Citation |
| 1 | Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. (Lust H, Gong S, Remiker A, Rossoff J) Pediatr Blood Cancer 2021 Oct;68(10):e29261 6 Citations |
| 2 | Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. (Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M) Br J Haematol 2021 Nov;195(3):429-432 2 Citations |
| 1 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. (Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M) Lancet 2021 Mar 06;397(10277):892-901 154 Citations |
| 2 | Peripherally restricted cannabinoid type 1 receptor (CB1R) antagonist, AM6545, potentiates stress-induced hypothalamic-pituitary-adrenal axis activation via a non-CB1R mechanism. (Roberts CJ, Hillard CJ) Endocrine 2021 Apr;72(1):297-300 1 Citation |
| 1 | Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia. (Phillips L, Pavisic J, Kaur D, Dorrello NV, Broglie L, Hijiya N) Blood Adv 2020 Sep 22;4(18):4358-4361 11 Citations |
| 1 | Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. (Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A, COVID-19 Global Rheumatology Alliance) Arthritis Rheumatol 2021 Jan;73(1):36-47 47 Citations |
| 1 | The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. (Kolkailah AA, Iskander M, Iskander F, Patel PP, Khan R, Doukky R) J Nucl Cardiol 2022 Feb;29(1):101-110 12 Citations |
| 1 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. (Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K) Clin Cancer Res 2020 Sep 15;26(18):4767-4776 52 Citations |
| 1 | The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date. (Kattoor AJ, Kolkailah AA, Iskander F, Iskander M, Diep L, Khan R, Doukky R) J Nucl Cardiol 2021 Dec;28(6):2799-2807 7 Citations |
| 2 | Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. (Abedin SM, Hamadani M) Expert Opin Investig Drugs 2020 May;29(5):423-427 6 Citations |
| 1 | Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. (Bromberg JS, Weir MR, Gaber AO, Yamin MA, Goldberg ID, Mayne TJ, Cal W, Cooper M) Transplantation 2021 Feb 01;105(2):443-450 9 Citations |
| 1 | Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. (Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ) Blood 2020 May 14;135(20):1739-1749 131 Citations |
| 1 | Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. (Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L) Cancer Chemother Pharmacol 2020 Apr;85(4):673-683 32 Citations |
| 11 | Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 11 Citations |
| 3 | Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. (Urrutia G, Salmonson A, Toro-Zapata J, de Assuncao TM, Mathison A, Dusetti N, Iovanna J, Urrutia R, Lomberk G) Mol Cancer Res 2020 Mar;18(3):448-462 9 Citations |
| 1 | Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. (McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL) J Thromb Haemost 2020 Feb;18(2):411-421 279 Citations |
| 1 | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. (Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, Gitlin SD, Kaminski M, Cusick A, Phillips T, Sood S, Talpaz M, Quiery A, Boonstra PS, Wilcox RA) Lancet Haematol 2019 Dec;6(12):e630-e637 163 Citations |
| 1 | Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. (Lindner JR, Belcik T, Widlansky M, Harmann LM, Karafin MS, Wandersee NJ, Puligandla M, Neuberg D, Linden J, Field JJ) PLoS One 2019;14(7):e0218783 7 Citations |
| 1 | Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm. (Iskander F, Iskander M, Gomez J, Doukky R) J Nucl Cardiol 2021 Jun;28(3):967-977 6 Citations |
| 6 | Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 54 Citations |
| 1 | Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature. (Gerrard DL, Wang Y, Gaddis M, Zhou Y, Wang J, Witt H, Lin S, Farnham PJ, Jin VX, Frietze SE) J Cell Biochem 2019 Mar;120(3):3056-3070 6 Citations |
| 1 | Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity. (Carter RLR, Talbot K, Hur WS, Meixner SC, Van Der Gugten JG, Holmes DT, Côté HCF, Kastrup CJ, Smith TW, Lee AYY, Pryzdial ELG) J Thromb Haemost 2018 Nov;16(11):2276-2288 30 Citations |
| 2 | Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? (Abid MB, Stromich J, Gundacker ND) Cancer Biol Ther 2019;20(2):138-140 7 Citations |
| 1 | Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging. (Doukky R, Nigatu A, Khan R, Anokwute C, Fughhi I, Ayoub A, Iskander F, Iskander M, Kola S, Sahyouni M, Karavolos K, Hota BN, Gomez J) J Nucl Cardiol 2020 Oct;27(5):1521-1532 15 Citations |
| 1 | Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. (Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C) Am J Hematol 2018 Nov;93(11):1394-1401 48 Citations |
| 1 | Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD. (Fidelman S, Mizrachi Zer-Aviv T, Lange R, Hillard CJ, Akirav I) Eur Neuropsychopharmacol 2018 May;28(5):630-642 40 Citations |
| 1 | Emerging drugs for the treatment of Myelofibrosis. (Shreenivas A, Mascarenhas J) Expert Opin Emerg Drugs 2018 Mar;23(1):37-49 11 Citations |
| 1 | P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts. (Dou C, Liu Z, Tu K, Zhang H, Chen C, Yaqoob U, Wang Y, Wen J, van Deursen J, Sicard D, Tschumperlin D, Zou H, Huang WC, Urrutia R, Shah VH, Kang N) Gastroenterology 2018 Jun;154(8):2209-2221.e14 114 Citations |
| 3 | Stress Promotes Drug Seeking Through Glucocorticoid-Dependent Endocannabinoid Mobilization in the Prelimbic Cortex. (McReynolds JR, Doncheck EM, Li Y, Vranjkovic O, Graf EN, Ogasawara D, Cravatt BF, Baker DA, Liu QS, Hillard CJ, Mantsch JR) Biol Psychiatry 2018 Jul 15;84(2):85-94 32 Citations |
| 1 | Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). (Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P) J Hematol Oncol 2017 Nov 02;10(1):171 25 Citations |
| 1 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. (Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA) Blood 2018 Jan 11;131(2):182-190 100 Citations |
| 1 | Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. (McBane Ii R, Loprinzi CL, Ashrani A, Perez-Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Le-Rademacher JG, Wysokinski WE) Thromb Haemost 2017 Oct 05;117(10):1952-1961 62 Citations |
| 3 | 17β-Estradiol Potentiates the Reinstatement of Cocaine Seeking in Female Rats: Role of the Prelimbic Prefrontal Cortex and Cannabinoid Type-1 Receptors. (Doncheck EM, Urbanik LA, DeBaker MC, Barron LM, Liddiard GT, Tuscher JJ, Frick KM, Hillard CJ, Mantsch JR) Neuropsychopharmacology 2018 Mar;43(4):781-790 28 Citations |
| 1 | In silico design of novel probes for the atypical opioid receptor MRGPRX2. (Lansu K, Karpiak J, Liu J, Huang XP, McCorvy JD, Kroeze WK, Che T, Nagase H, Carroll FI, Jin J, Shoichet BK, Roth BL) Nat Chem Biol 2017 May;13(5):529-536 184 Citations |
| 3 | Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Dec;35(4):528-535 46 Citations |
| 1 | Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66 5 Citations |
| 1 | Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. (Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J) J Clin Oncol 2016 May 20;34(15):1764-71 118 Citations |
| 4 | Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 16 Citations |
| 1 | Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease? (Field JJ) Hematology Am Soc Hematol Educ Program 2015;2015:426-32 5 Citations |
| 1 | Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. (Falchook GS, Bastida CC, Kurzrock R) Semin Oncol 2015 Dec;42(6):832-48 76 Citations |
| 1 | Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. (Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J) Leukemia 2016 Jun;30(6):1413-5 6 Citations |
| 2 | CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats. (McReynolds JR, Doncheck EM, Vranjkovic O, Ganzman GS, Baker DA, Hillard CJ, Mantsch JR) Psychopharmacology (Berl) 2016 Jan;233(1):99-109 31 Citations |
| 1 | Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 27 Citations |
| 1 | Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. (Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, Liu C, McDonald DG, Pidala J, Yu XZ) PLoS One 2015;10(9):e0137641 67 Citations |
| 1 | Disruption of peri-adolescent endocannabinoid signaling modulates adult neuroendocrine and behavioral responses to stress in male rats. (Lee TT, Hill MN, Hillard CJ, Gorzalka BB) Neuropharmacology 2015 Dec;99:89-97 19 Citations |
| 1 | BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons. (Zhong P, Liu Y, Hu Y, Wang T, Zhao YP, Liu QS) J Neurosci 2015 Mar 11;35(10):4469-81 33 Citations |
| 1 | Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):214-221.e1 52 Citations |
| 1 | Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. (Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F) Cancer Res 2015 Feb 01;75(3):594-604 63 Citations |
| 2 | Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways. (Baker JE, Su J, Koprowski S, Dhanasekaran A, Aufderheide TP, Gross GJ) J Pharmacol Exp Ther 2015 Mar;352(3):429-37 10 Citations |
| 1 | Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. (Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ) Biomed Res Int 2014;2014:583794 42 Citations |
| 1 | Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? (Barosi G, Zhang MJ, Gale RP) Leukemia 2014 Nov;28(11):2267-70 21 Citations |
| 4 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. (Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B) Br J Cancer 2014 Jul 08;111(1):85-93 66 Citations |
| 1 | Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. (Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, Gandhi M, Carty SE, Hodak SP, Luo J, Dacic S, Yu YP, Nikiforova MN, Ferris RL, Altschuler DL, Nikiforov YE) Proc Natl Acad Sci U S A 2014 Mar 18;111(11):4233-8 191 Citations |
| 1 | The role of adenosine signaling in sickle cell therapeutics. (Field JJ, Nathan DG, Linden J) Hematol Oncol Clin North Am 2014 Apr;28(2):287-99 23 Citations |
| 1 | Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. (Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT) Mol Cancer Ther 2014 May;13(5):1246-58 34 Citations |
| 3 | Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. (Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ) Pharmacol Biochem Behav 2014 Feb;117:17-24 38 Citations |
| 1 | The memory-enhancing effects of hippocampal estrogen receptor activation involve metabotropic glutamate receptor signaling. (Boulware MI, Heisler JD, Frick KM) J Neurosci 2013 Sep 18;33(38):15184-94 148 Citations |
| 1 | Clarifying the use of ruxolitinib in patients with myelofibrosis. (Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO) Oncology (Williston Park) 2013 Jul;27(7):706-14 9 Citations |
| 1 | Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. (Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT) Clin Cancer Res 2013 Oct 15;19(20):5658-74 46 Citations |
| 1 | Eltrombopag-associated hyperpigmentation. (Braunstein I, Wanat KA, Elenitsas R, Xu X, Frey N, Rosenbach M) JAMA Dermatol 2013 Sep;149(9):1112-5 11 Citations |
| 1 | ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. (Sun Y, Nowak KA, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, Liu N, Werner-Wasik M, Wasik MA, Dicker AP, Lu B) Mol Cancer Ther 2013 May;12(5):696-704 49 Citations |
| 1 | RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. (Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA) Mol Cancer Res 2013 Jun;11(6):616-27 11 Citations |
| 1 | Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. (Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG) Blood 2013 Apr 25;121(17):3329-34 78 Citations |
| 1 | Emerging drugs for myelofibrosis. (Atallah E, Verstovsek S) Expert Opin Emerg Drugs 2012 Dec;17(4):555-70 5 Citations |
| 3 | AMP kinase activation improves angiogenesis in pulmonary artery endothelial cells with in utero pulmonary hypertension. (Teng RJ, Du J, Afolayan AJ, Eis A, Shi Y, Konduri GG) Am J Physiol Lung Cell Mol Physiol 2013 Jan 01;304(1):L29-42 43 Citations |
| 1 | Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. (Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, Iskandrian AE) JACC Cardiovasc Imaging 2012 Oct;5(10):1014-21 46 Citations |
| 1 | Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. (Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B) Int J Radiat Oncol Biol Phys 2012 Nov 15;84(4):e525-31 17 Citations |
| 1 | Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. (McLaughlin RJ, Hill MN, Bambico FR, Stuhr KL, Gobbi G, Hillard CJ, Gorzalka BB) Eur Neuropsychopharmacol 2012 Sep;22(9):664-71 83 Citations |
| 2 | Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. (Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB) Endocrinology 2012 Jan;153(1):29-41 29 Citations |
| 2 | Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. (Vaughn LK, Mantsch JR, Vranjkovic O, Stroh G, Lacourt M, Kreutter M, Hillard CJ) Neuroscience 2012 Mar 01;204:117-24 36 Citations |
| 2 | Extracellular signal-regulated kinase signaling in the ventral tegmental area mediates cocaine-induced synaptic plasticity and rewarding effects. (Pan B, Zhong P, Sun D, Liu QS) J Neurosci 2011 Aug 03;31(31):11244-55 54 Citations |
| 4 | Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. (Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT, Karatsoreos IN, Mackie K, Viau V, Pickel VM, McEwen BS, Liu QS, Gorzalka BB, Hillard CJ) J Neurosci 2011 Jul 20;31(29):10506-15 271 Citations |
| 1 | Pyrazolyl methyls prescribe the electronic properties of iron(II) tetra(pyrazolyl)lutidine chloride complexes. (Morin TJ, Wanniarachchi S, Gwengo C, Makura V, Tatlock HM, Lindeman SV, Bennett B, Long GJ, Grandjean F, Gardinier JR) Dalton Trans 2011 Aug 21;40(31):8024-34 14 Citations |
| 1 | Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. (Gore E, Bae K, Langer C, Extermann M, Movsas B, Okunieff P, Videtic G, Choy H) Clin Lung Cancer 2011 Mar;12(2):125-30 24 Citations |
| 1 | Using sterics to promote reactivity in fac-Re(CO)3 complexes of some 'non-innocent' NNN-pincer ligands. (Wanniarachchi S, Liddle BJ, Toussaint J, Lindeman SV, Bennett B, Gardinier JR) Dalton Trans 2011 Sep 21;40(35):8776-87 19 Citations |
| 1 | Targeting iNKT cells for the treatment of sickle cell disease. (Field JJ, Nathan DG, Linden J) Clin Immunol 2011 Aug;140(2):177-83 38 Citations |
| 3 | Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. (Ho WS, Patel S, Thompson JR, Roberts CJ, Stuhr KL, Hillard CJ) Br J Pharmacol 2010 Jun;160(3):736-46 10 Citations |
| 1 | Endogenous cannabinoid signaling is essential for stress adaptation. (Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V) Proc Natl Acad Sci U S A 2010 May 18;107(20):9406-11 267 Citations |
| 1 | Identification and characterization of the first small molecule inhibitor of MDMX. (Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA) J Biol Chem 2010 Apr 02;285(14):10786-96 173 Citations |
| 1 | Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. (Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB) Neuropsychopharmacology 2009 Dec;34(13):2733-45 229 Citations |
| 3 | D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. (Pan B, Hillard CJ, Liu QS) J Neurosci 2008 Dec 24;28(52):14018-30 108 Citations |
| 1 | Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. (Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, Malan TP Jr, Yamamura HI, Ossipov MH, King T, Lai J, Porreca F, Vanderah TW) J Neurosci 2008 Nov 05;28(45):11593-602 75 Citations |
| 1 | First-row transition-metal complexes of a new pentadentate ligand, alpha,alpha,alpha',alpha'-tetra(pyrazolyl)lutidine. (Morin TJ, Bennett B, Lindeman SV, Gardinier JR) Inorg Chem 2008 Sep 01;47(17):7468-70 21 Citations |
| 2 | Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. (Hillard CJ, Ho WS, Thompson J, Gauthier KM, Wheelock CE, Huang H, Hammock BD) Br J Pharmacol 2007 Nov;152(5):691-8 26 Citations |
| 1 | Celecoxib toxicity is cell cycle phase specific. (Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, Trask DK) Cancer Res 2007 Apr 15;67(8):3801-8 36 Citations |
| 1 | Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. (Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE, Trask DK) Mol Carcinog 2007 Oct;46(10):857-64 18 Citations |
| 1 | Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. (Rademacher DJ, Hillard CJ) Prog Neuropsychopharmacol Biol Psychiatry 2007 Apr 13;31(3):633-41 67 Citations |
| 1 | Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. (Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB) Neuropsychopharmacology 2006 Dec;31(12):2591-9 103 Citations |
| 2 | Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. (Carrier EJ, Auchampach JA, Hillard CJ) Proc Natl Acad Sci U S A 2006 May 16;103(20):7895-900 350 Citations |
| 1 | Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. (Patel S, Roelke CT, Rademacher DJ, Hillard CJ) Eur J Neurosci 2005 Feb;21(4):1057-69 250 Citations |
| 1 | Celecoxib and radiation therapy in non-small-cell lung cancer. (Gore E) Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):10-4 22 Citations |
| 1 | Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. (Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ) Neuroscience 2004;129(3):743-50 123 Citations |
| 1 | Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets. (Heitmeier MR, Kelly CB, Ensor NJ, Gibson KA, Mullis KG, Corbett JA, Maziasz TJ) J Biol Chem 2004 Dec 17;279(51):53145-51 40 Citations |
| 1 | Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. (Alcindor D, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR) Anesthesiology 2004 Mar;100(3):547-54 42 Citations |
| 1 | Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. (Tanaka K, Ludwig LM, Krolikowski JG, Alcindor D, Pratt PF, Kersten JR, Pagel PS, Warltier DC) Anesthesiology 2004 Mar;100(3):525-31 104 Citations |
| 1 | Rethinking the toxic methanol level. (Kostic MA, Dart RC) J Toxicol Clin Toxicol 2003;41(6):793-800 47 Citations |
| 1 | Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. (Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD, Vita JA) Hypertension 2003 Sep;42(3):310-5 144 Citations |
| 1 | Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. (Rademacher DJ, Patel S, Hopp FA, Dean C, Hillard CJ, Seagard JL) Am J Physiol Heart Circ Physiol 2003 May;284(5):H1570-6 31 Citations |
| 2 | The CB1 receptor antagonist SR141716 enhances stimulus-induced activation of the primary somatosensory cortex of the rat. (Patel S, Gerrits R, Muthian S, Greene AS, Hillard CJ) Neurosci Lett 2002 Dec 25;335(2):95-8 14 Citations |
| 1 | Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. (Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ) Gynecol Oncol 2002 Feb;84(2):241-4 19 Citations |
| 1 | Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. (Patel S, Hillard CJ) J Pharmacol Exp Ther 2001 May;297(2):629-37 76 Citations |
| 1 | Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells. (Sorokin A, Kozlowski P, Graves L, Philip A) J Biol Chem 2001 Jun 15;276(24):21521-8 63 Citations |
| 1 | Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. (Tyler K, Hillard CJ, Greenwood-Van Meerveld B) Eur J Pharmacol 2000 Dec 08;409(2):207-11 56 Citations |
| 1 | Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. (Hillard CJ, Muthian S, Kearn CS) FEBS Lett 1999 Oct 08;459(2):277-81 91 Citations |
| 1 | Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. (Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ) J Neurochem 1999 Jun;72(6):2379-87 104 Citations |
| 2 | N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. (Pratt PF, Hillard CJ, Edgemond WS, Campbell WB) Am J Physiol 1998 Jan;274(1):H375-81 110 Citations |
| 1 | Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. (Robins HI, Longo WL, Steeves RA, Cohen JD, Schmitt CL, Neville AJ, O'Keefe S, Lagoni R, Riggs C) Int J Radiat Oncol Biol Phys 1990 Apr;18(4):909-20 28 Citations |
| 1 | Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. (Robins HI, Longo WL, Lagoni RK, Neville AJ, Hugander A, Schmitt CL, Riggs C) Cancer Res 1988 Nov 15;48(22):6587-92 29 Citations |
